Phase I

Trial

Single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of EHP-101

Objective

Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Status

Completed | LEARN MORE

ClinicalTrials.gov Identifier: NCT03745001

Phase IIa

Trial

Double-Blind, Randomized, Intracohort Placebo-Controlled, Multicenter Study of EHP-101

Objective

Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis

Status

Enrolling patients in the United States, Australia, and New Zealand. We plan to enroll approximately 36 patients in a total of an estimated 30 centers and anticipate starting to get preliminary results in 2022

ClinicalTrials.gov Identifier: NCT04166552